Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis - University of Regensburg Publication Server

URN to cite this document:: urn:nbn:de:bvb:355-epub-746760
DOI to cite this document:: 10.5283/epub.74676

Heidenreich, Silke ; Egger-Heidrich, Katharina ; Halter, Jörg P. ; Jost, Lasse ; Stölzel, Friedrich ; Perl, Markus ; Denk, Alexander

; Edinger, Matthias

; Herr, Wolfgang ; Kröger, Nicolaus ; Wolff, Daniel

; Ayuk, Francis ; Fante, Matthias A.

License: Creative Commons Attribution 4.0
PDF - Published Version
(718kB)

Date of publication of this fulltext: 28 Jan 2025 05:27

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Export bibliographical data

Abstract

Belumosudil is a first in class ROCK2-inhibitor approved by the FDA for the 3rd line treatment of chronic graft-versus-host disease (cGvHD). In this retrospective real-world analysis, we report safety and efficacy data of belumosudil treatment from 5 German/Swiss transplant centers. A total of 33 adult patients (median age 59 years) with moderate (n = 2) or severe (n = 31) cGvHD were treated on ...